1. South Africa Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited

APNHF
Aspen Pharmacare Holdings LimitedUS flagOther OTC
8.70
USD
- -
- -
3.86BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
42.4
64.71
79.11
78
90.3
83.95
77.81
73.73
82.73
85.22
91.65
100.64
97.66
Basic EPS, GAAP
7.73
10.98
11.4
9.42
11.24
13.23
14.16
10.22
10.53
14.32
11.77
9.91
-2.44
Free Cash Flow per Basic Share
-0.74
3.59
5.26
0.88
10.93
-2.65
5.3
18.09
14.95
11.86
12.43
14.01
11.62
Dividend per Share
1.57
1.57
1.97
2.19
2.7
2.88
3.15
- -
- -
2.64
3.28
3.43
3.61
Book Value per Share
8.76
50.51
60.49
66.83
73.47
84.17
94.95
105.15
115.76
124.41
135.41
141.33
135.38
Tangible Book Value per Share
-4.63
-29.52
-24.98
-27.61
-51.61
-63.35
-37.04
-20.15
13.42
27.12
39.48
29.58
28.11
Basic Weighted Avg Shares
455
456
456
456
456
456
456
456
456
453
444
444
444
Sales/Revenue/Turnover
19,308
29,515
36,100
35,600
41,213
38,314
35,514
33,659
37,766
38,606
40,709
44,706
43,363
Operating Margin (%)
26.12
25.16
23.27
28.65
23.66
25.74
24.3
24.08
21.51
22.77
20.26
23.37
19.89
Depreciation Expense
- -
824
1,000
1,200
1,267
1,372
1,274
1,603
1,653
1,713
1,788
1,973
2,089
Net Income, GAAP
3,520
5,008
5,200
4,300
5,128
6,037
6,463
4,664
4,806
6,488
5,228
4,404
-1,083
Effective Tax Rate (%)
21.72
21.25
20
29.51
17.98
16.64
28.54
19.49
19.89
20.24
20.24
22.93
- -
Profit Margin (%)
18.23
16.97
14.4
12.08
12.44
15.76
18.2
13.86
12.73
16.81
12.84
9.85
-2.5
Working Capital
2,912
15,171
10,900
16,100
2,557
11,293
16,113
18,659
-4,046
11,166
21,352
19,784
21,206
LT Debt
8,924
29,916
25,500
32,700
28,978
46,725
39,713
36,019
266
10,582
21,375
25,141
31,508
Total Equity
22,799
28,876
34,100
42,500
42,391
49,375
54,213
69,217
65,627
70,942
86,236
84,861
84,893
Return on Invested Capital (%)
11.67
10.91
9.59
8.99
8.97
8.23
5.82
6.05
6.37
7.52
6.22
6.74
- -
Return on Capital (%)
23.15
14.94
10.68
8.13
8.87
8.82
8.58
6.6
6.87
9.08
7.48
6.49
- -
Return on Common Equity (%)
80.99
37.06
20.54
14.8
16.02
16.78
15.81
10.21
9.53
11.88
8.97
7.16
-1.76

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.12%
4.58%
0.04%
Free Cash Flow
84.06%
-8.05%
-17.12%
Net Income, GAAP
-12.28%
-24.35%
-124.59%
Sales/Revenue/Turnover
2.15%
5.34%
-3%
Total Cash Common Dividend
- -
- -
4.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
44,706
2025
- -
- -
- -
- -
43,363
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9.91
2025
- -
- -
- -
- -
-2.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.43
2025
- -
- -
- -
- -
3.61
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Stephen Bradley Saad
Full Time Employees
8,867
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Aspen Place Durban South Africa
IPO Date
Apr 29, 2010
Website
aspenpharma.com
Similar Companies
Piramal Pharma Limited (PPLPHARMA.NS)
Cannara Biotech Inc. (LOVE.V)
Next Science Limited (NXSCF)
Orexo AB (publ) (ORX.ST)
The BC Bud Corporation (BCBC.CN)
Ipsen S.A. (IPSEF)
Business
Aspen Pharmacare Holdings Limited is a global specialty and branded multinational pharmaceutical company that markets and manufactures a broad range of post-patent branded medicines and domestic brands for hospital and consumer markets. The company operates through key segments of Manufacturing and Commercial Pharmaceuticals, offering injectable products such as anaesthetics, anticoagulants, antithrombotic agents, analgesics and hormone replacement medicines; prescription medicines; over-the-counter medicines; and infant nutritionals; with manufacturing capabilities spanning steriles, oral solid dose forms, liquids, semi-solids, biologicals and active pharmaceutical ingredients. Aspen maintains 24 manufacturing facilities across 15 sites, holding approvals from stringent regulators including the US FDA, Australian TGA and EDQM, and serves patients in over 115 countries through offices in more than 46 countries and territories, targeting emerging and developed markets with over 9300 employees. Founded with a 170-year heritage and headquartered in Durban, South Africa, the company recently reports strong financial momentum with revenue increasing 10% for the year ended 30 June 2025, driven by robust second-half performance in Commercial Pharmaceuticals; builds strategic focus on core therapeutic portfolios following divestitures like the 2022 sale of select South African brands to Acino; and continues global expansion in injectables and manufacturing while advancing technology transfers for vaccines in Africa.